

Johnson
235241

=> fil reg

FILE 'REGISTRY' ENTERED AT 13:23:09 ON 03 JUN 94
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 1994 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 27 MAY 94 HIGHEST RN 155417-12-2
DICTIONARY FILE UPDATES: 03 JUN 94 HIGHEST RN 155417-12-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 1994

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

=> e factor viii/cn

E1	1	FACTOR VI/CN
E2	1	FACTOR VI (VITAMIN B12 ANALOG)/CN
E3	3 -->	FACTOR VIII/CN
E4	1	FACTOR X/CN
E5	1	FACTOR XA/CN
E6	1	FACTOR XA-1/CN
E7	1	FACTOR XIIA/CN
E8	1	FACTOR XIII/CN
E9	1	FACTOR420 HYDROGENASE/CN
E10	1	FACTORATE/CN
E11	1	FACTREL/CN
E12	1	FACTUMYCIN/CN

=> s e3

L1 3 "FACTOR VIII"/CN

=> e f viii c/cn

E1	1	F RESIN/CN
E2	2	F STEEL/CN
E3	0 -->	F VIII C/CN
E4	1	F-0000/CN
E5	1	F-0000-10/CN
E6	1	F-0000-20/CN
E7	1	F-0000-P-SULFURIZED/CN
E8	1	F-0008-P/CN
E9	1	F-0008-P-SULFURIZED/CN
E10	1	F-0208/CN
E11	2	F-10/CN
E12	1	F-102 GAS/CN

=> fil ca

FILE 'CA' ENTERED AT 13:24:01 ON 03 JUN 94
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 1994 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1967 - 28 May 1994 (940528/ED) VOL 120 ISS 22

To help control your online searching costs, consider using the
HCA File when conducting SmartSELECT searches with large

numbers of terms.

=> s (l1 or ((factor or f)(w)viii(w)c)/ia)

3765 L1
138676 FACTOR/BI
271357 FACTOR/AB
322065 FACTOR/IA
 (FACTOR/BI,AB)
36612 F/BI
235833 F/AB
252964 F/IA
 (F/BI,AB)
17541 VIII/BI
16019 VIII/AB
29306 VIII/IA
 (VIII/BI,AB)
174863 C/BI
1081855 C/AB
1147451 C/IA
 (C/BI,AB)
200 ((FACTOR OR F)(W)VIII(W)C)/IA
L2 3786 (L1 OR ((FACTOR OR F)(W)VIII(W)C)/IA)

=> s 12 and (organic polymer or detergent)/ia

129084 ORGANIC/BI
1570 ORGANIC/AB
130294 ORGANIC/IA
 (ORGANIC/BI,AB)
322038 POLYMER/BI
244540 POLYMER/AB
447877 POLYMER/IA
 (POLYMER/BI,AB)
508 ORGANIC POLYMER/IA
 ((ORGANIC(W)POLYMER)/IA)
21540 DETERGENT/BI
30510 DETERGENT/AB
40407 DETERGENT/IA
 (DETERGENT/BI,AB)
L3 36 L2 AND (ORGANIC POLYMER OR DETERGENT)/IA

=> s 13 and plasma/ia

242303 PLASMA/BI
331095 PLASMA/AB
382764 PLASMA/IA
 (PLASMA/BI,AB)
L4 23 L3 AND PLASMA/IA

=> s 14 and (stabil? or stabl? or buffer?)/ia

207232 STABIL?/BI
353700 STABIL?/AB
435736 STABIL?/IA
 (STABIL?/BI,AB)
40422 STABL?/BI

235041 STABL?/AB
256929 STABL?/IA
(STABL?/BI,AB)

13484 BUFFER?/BI
115884 BUFFER?/AB
118760 BUFFER?/IA
(BUFFER?/BI,AB)

L5 3 L4 AND (STABIL? OR STABL? OR BUFFER?)/IA

=> d 1-3 .mh;s 14 not 15

L5 ANSWER 1 OF 3 CA COPYRIGHT 1994 ACS

TI Preparation of intermediate-purity factor VIII concentrate
by direct

gel filtration of cryoprecipitate

SO Vox Sang., 65(4), 251-7

AU Teh, L. C.

PY 1993

AN CA120(22):279944a CA

AB The authors report a new method to produce a solvent/
detergent-treated and severe dry heat-treated factor VIII
(FVIII) conc. (3-6 IU FVIII:C/mg protein). This method,
which uses a

single purifn. step after cryopptn., is suitable for
scale-up to

prodn. levels. FVIII was obtained from solvent/**detergent**-
treated cryoppt. by a single gel filtration step using

Sephacryl

S-400HR. The freeze-dried product was **stable** to heating at
80.degree. for 72 h. The yield of the solvent/**detergent**
and severe dry heat-treated product was 230 IU FVIII:C/kg
plasma. The reconstituted product gave a 10% loss in FVIII:C
activity after heating at 37.degree. for 6 h. The

feasibility of

this method suggests that gel filtration using S-400HR can
be used

solely or as part of a purifn. process for the prepn. of
high-purity

FVIII concs.

L5 ANSWER 2 OF 3 CA COPYRIGHT 1994 ACS

TI Large-scale preparation of a highly purified solvent-
detergent treated factor VIII concentrate

SO Vox Sang., 60(3), 141-7

AU Myers, Robert; Wickerhauser, Milan; Charamella, Leigh;
Simon,

Louise; Nummy, William; Brodniewicz-Proba, Teresa

PY 1991

AN CA115(4):35559j CA

AB Large-scale adaptation of a recently reported glycine pptn.
method

for the prodn. of factor VIII (FVIII) conc. is described.

Scaling up

of the method required some modification including the addn. of $\text{Al}(\text{OH})_3$ to the glycine **buffer** to reduce the level of contaminating proteins in the final prepn. and the use of centrifugation to replace filtration by glass beads. Furthermore, the resultant product was virus inactivated by incorporation of the org. solvent and **detergent** technique. At industrial level, the modified method gave a good recovery of FVIII activity (230 IU/L **plasma**) with high purity (4 IU/mg protein). The final product, after virus inactivation and lyophilization, yielded 185 IU of FVIII activity per L of starting **plasma** and was considered to be suitable for clin. evaluation.

L5 ANSWER 3 OF 3 CA COPYRIGHT 1994 ACS
TI Progress in purification of virus-inactivated factor VIII concentrates. Three generations of solvent/**detergent** treated **plasma** derivatives
SO Arzheim.-Forsch., 39(10), 1302-5
AU Schwinn, H.; Smith, A.; Wolter, D.
PY 1989
AN CA112(2):11823c CA
AB A prodn. process of a newly developed highly purified and virus-inactivated Factor (F) VIII-conc. (Octa V.I. and Octavi) is presented. Taking advantage of a selective resin matrix and the solvent/**detergent** procedure for virus inactivation - known not to denaturate proteins - a product of a specific activity .gtoreq. 100 IU F VIII/mg was developed in the final container without the use of an immuno-affinity adsorption step. The main steps of the procedure are: pooled cryoppt. is extd., the ext. is cleared from fibrinogen at + 10.degree. and virus-inactivated at + 28.degree. after addn. of tri-Bu phosphate (TNBP) and **detergent**. Thereafter the ext. is brought in contact to a F VIII-selective anion exchange resin using a chromatog. column. TNBP and the **detergent** are removed by an extensive washing process and the F VIII-activity is concd. in a fraction, ready for filling, by means of a cascade of washing- and elution-buffers. The product is free from coagulate protein and .gamma.-globulins. The F VIIIC: Ag/F VIII: C-ratio is about unity, suggesting the F VIII-mol. remained in its native state. The development of highly purified F VIII conc.

is based on 2 previous products of lesser purity (specific activity of about 1 and 10 IU/mg). The evolution is shown by a comparison of detailed anal. data.

L6 20 L4 NOT L5

=> s 16 and (amino acid or (arginine and glycine) or (arg and gly))/ia

263254 AMINO/BI
307723 AMINO/AB
418448 AMINO/IA
 (AMINO/BI,AB)
1171914 ACID/BI
1113516 ACID/AB
1705208 ACID/IA
 (ACID/BI,AB)
212257 AMINO ACID/IA
 ((AMINO(W)ACID)/IA)
19216 ARGININE/BI
35317 ARGININE/AB
42730 ARGININE/IA
 (ARGININE/BI,AB)
30514 GLYCINE/BI
41491 GLYCINE/AB
58773 GLYCINE/IA
 (GLYCINE/BI,AB)
1321 ARG/BI
13648 ARG/AB
14124 ARG/IA
 (ARG/BI,AB)
1741 GLY/BI
20154 GLY/AB
20723 GLY/IA
 (GLY/BI,AB)

L7 0 L6 AND (AMINO ACID OR (ARGININE AND GLYCINE) OR (ARG AND G LY))/IA

=> s 16 and carbohydrate?/ia

64782 CARBOHYDRATE?/BI
53978 CARBOHYDRATE?/AB
91612 CARBOHYDRATE?/IA
 (CARBOHYDRATE?/BI,AB)

L8 0 L6 AND CARBOHYDRATE?/IA

=> dis his

(FILE 'HOME' ENTERED AT 13:21:56 ON 03 JUN 94)
SET PAGELength SCROLL

FILE 'REGISTRY' ENTERED AT 13:23:09 ON 03 JUN 94

L1 E FACTOR VIII/CN
 3 S E3
 E F VIII C/CN

FILE 'CA' ENTERED AT 13:24:01 ON 03 JUN 94

L2 3786 S (L1 OR ((FACTOR OR F)(W)VIII(W)C)/IA)
L3 36 S L2 AND (ORGANIC POLYMER OR DETERGENT)/IA
L4 23 S L3 AND PLASMA/IA
L5 3 S L4 AND (STABIL? OR STABL? OR BUFFER?)/IA
L6 20 S L4 NOT L5
L7 0 S L6 AND (AMINO ACID OR (ARGININE AND GLYCINE)
OR (ARG AN
L8 0 S L6 AND CARBOHYDRATE?/IA

=> s (((factor or f)(w)viii(w)c)/ia)
 138676 FACTOR/BI
 271357 FACTOR/AB
 322065 FACTOR/IA
 (FACTOR/BI,AB)
 36612 F/BI
 235833 F/AB
 252964 F/IA
 (F/BI,AB)
 17541 VIII/BI
 16019 VIII/AB
 29306 VIII/IA
 (VIII/BI,AB)
 174863 C/BI
 1081855 C/AB
 1147451 C/IA
 (C/BI,AB)
L9 200 (((FACTOR OR F)(W)VIII(W)C)/IA)

=> s 19 and (prepar? or prepn)/ia
 832815 PREPAR?/BI
 22731 PREPAR?/AB
 851018 PREPAR?/IA
 (PREPAR?/BI,AB)
 1239267 PREPN/BI
 228922 PREPN/AB
 1382810 PREPN/IA
 (PREPN/BI,AB)
L10 46 L9 AND (PREPAR? OR PREPN)/IA

=> s 110 not 15
L11 45 L10 NOT L5

=> d 1-45 an ti so au pi ai py;s 16 not 111

L11 ANSWER 1 OF 45 CA COPYRIGHT 1994 ACS
AN CA120(18):226634t CA
TI Characterization of factors affecting the stability of
frozen

heparinized plasma
SO Vox Sang., 65(4), 258-70
AU Palmer, D. S.; Rosborough, D.; Perkins, H.; Bolton, T.;
Rock, G.;
Ganz, P. R.
PY 1993

L11 ANSWER 2 OF 45 CA COPYRIGHT 1994 ACS
AN CA120(13):157515r CA
TI Purification of Factor VIII complex from serum
SO PCT Int. Appl., 34 pp.
IN Bhattacharya, Prabir; Motokubotta, Toshiharu
PI WO 9322337 A1 931111
AI WO 93-US4058 930430
PY 1993

L11 ANSWER 3 OF 45 CA COPYRIGHT 1994 ACS
AN CA120(5):52855y CA
TI Egg yolk fraction for increasing recombinant protein
production in
mammalian cell culture
SO PCT Int. Appl., 20 pp.
IN Kongerslev, Leif; Pedersen, John
PI WO 9322425 A1 931111
AI WO 93-DK138 930423
PY 1993

L11 ANSWER 4 OF 45 CA COPYRIGHT 1994 ACS
AN CA119(8):80196g CA
TI Process for purifying Factor VIII, and preparations so
obtained
SO Eur. Pat. Appl., 7 pp.
IN Grandgeorge, Michel; Lutsch, Charles
PI EP 534812 A1 930331
AI EP 92-402378 920901
PY 1993

L11 ANSWER 5 OF 45 CA COPYRIGHT 1994 ACS
AN CA118(20):197865v CA
TI Factor VIII:c concentrate virus
inactivated: Progress in purification by using classic
chromatographic methods
SO Vox Sang., 64(1), 13-18
AU Arrigi, Silvana; Pacenti, Lorenzo; Borri, Maria Giuseppina
PY 1993

L11 ANSWER 6 OF 45 CA COPYRIGHT 1994 ACS
AN CA117(6):55742h CA
TI Factor VIII yields from anticoagulant exchanged Haemonetics
Ultralite plasma
SO Dev. Hematol. Immunol., 26(Coagulation Blood Transfus.),
49-54
AU Speak, J.; Cumming, A. M.; Wensley, R. T.

PY 1991

L11 ANSWER 7 OF 45 CA COPYRIGHT 1994 ACS
AN CA116(8):67159r CA
TI Method for preparing high-purity factor VIII including a rapid immunoabsorption step
SO PCT Int. Appl., 27 pp.
IN Chtourou, Abdessatar
PI WO 9118017 A1 911128
AI WO 91-FR400 910517
PY 1991

L11 ANSWER 8 OF 45 CA COPYRIGHT 1994 ACS
AN CA114(22):214230w CA
TI Further evidence that the residual vWf:Ag in porcine FVIII:C induces human platelet aggregation
SO Haemostasis, 20(5), 289-95
AU Saniabadi, A. R.; Marney, Y.; Belch, J. J. F.; Lowe, G. D. O.;
Barbenel, J. C.; Madhok, R.; Forbes, C. D.
PY 1990

L11 ANSWER 9 OF 45 CA COPYRIGHT 1994 ACS
AN CA111(22):201439j CA
TI Inactivation and removal of human immunodeficiency virus in monoclonal-purified antihemophilic factor (human) (Humofil)
SO Thromb. Res., 55(5), 627-34
AU Piszkiwicz, Dennis; Sun, Chong Son; Tondreau, Sue C.
PY 1989

L11 ANSWER 10 OF 45 CA COPYRIGHT 1994 ACS
AN CA111(22):201435e CA
TI Severely heated therapeutic factor VIII concentrate of high specific activity
SO Vox Sang., 57(2), 97-103
AU Winkelman, L.; Owen, N. E.; Evans, D. R.; Evans, H.; Haddon, M. E.;
Smith, J. K.; Prince, P. J.; Williams, J. D.; Lane, R. S.
PY 1989

L11 ANSWER 11 OF 45 CA COPYRIGHT 1994 ACS
AN CA111(15):130280n CA
TI Fluoroplastic immunoaffinity columns for purification of blood proteins
SO U.S., 5 pp.
IN Zimmerman, Theodore S.; Fulcher, Carol A.
PI US 4831118 A 890516
AI US 87-83670 870807
PY 1989

L11 ANSWER 12 OF 45 CA COPYRIGHT 1994 ACS
 AN CA111(9):74364d CA
 TI A two-stage affinity ultrapurification process for
 polypeptides such
 as coagulation factor VIII:C
 SO Eur. Pat. Appl., 17 pp.
 IN Griffith, Michael J.; Neslund, Gerald; Liu, Shu Len
 PI EP 286323 A2 881012
 AI EP 88-302905 880331
 PY 1988

L11 ANSWER 13 OF 45 CA COPYRIGHT 1994 ACS
 AN CA111(1):4918p CA
 TI Storage of whole blood for up to 24 hours at ambient
 temperature
 prior to component preparation
 SO Vox Sang., 56(3), 145-50
 AU Pietersz, R. N. I.; De Korte, D.; Reesink, H. W.; Dekker,
 W. J. A.;
 Van den Ende, A.; Loos, J. A.
 PY 1989

L11 ANSWER 14 OF 45 CA COPYRIGHT 1994 ACS
 AN CA110(20):179379v CA
 TI Subcutaneous injection of desmopressin (DDAVP): evaluation
 of a
 new, more concentrated preparation
 SO Haemostasis, 19(1), 38-44
 AU Koehler, Michael; Hellstern, P.; Tarrach, H.; Bambauer, R.;
 Wenzel,
 E.; Jutzler, G. A.
 PY 1989

L11 ANSWER 15 OF 45 CA COPYRIGHT 1994 ACS
 AN CA110(18):160275m CA
 TI Preparation of cryoprecipitate in blood bags
 SO Pharmazie, 44(1), 71
 AU Uteg, K. H.; Tausendfreund, K.
 PY 1989

L11 ANSWER 16 OF 45 CA COPYRIGHT 1994 ACS
 AN CA110(13):112360p CA
 TI Factor VIII procoagulant protein interacts with phospholipid
 vesicles via its 80 kDa light chain
 SO Thromb. Haemostasis, 60(3), 442-6
 AU Kemball-Cook, G.; Edwards, S. J.; Sewerin, K.; Andersson,
 L. O.;
 Barrowcliffe, T. W.
 PY 1988

L11 ANSWER 17 OF 45 CA COPYRIGHT 1994 ACS
 AN CA110(4):29087j CA
 TI Preparation of factor VIII:C

-free blood plasma
SO Ger. Offen., 5 pp.
IN Becker, Udo; Heimbürger, Norbert; Braun, Konrad
PI DE 3707213 A1 880915
AI DE 87-3707213 870306
PY 1988

L11 ANSWER 18 OF 45 CA COPYRIGHT 1994 ACS
AN CA109(17):143979f CA
TI High-level inducible expression of heterologous genes using
plasmids
encoding a receptor and plasmids containing a gene
responsive to the
ligand-receptor complex, and cells containing these plasmids
SO PCT Int. Appl., 35 pp.
IN Kaufman, Randal J.; Israel, David
PI WO 8800975 A1 880211
AI WO 87-US1871 870731
PY 1988

L11 ANSWER 19 OF 45 CA COPYRIGHT 1994 ACS
AN CA109(16):134870m CA
TI Studies on the procurement of blood coagulation factor
VIII. In
vitro studies on blood components prepared in
half-strength citrate anticoagulant 18 hours after
phlebotomy
SO Vox Sang., 55(1), 9-13
AU Griffin, B.; Bell, K.; Prowse, C.
PY 1988

L11 ANSWER 20 OF 45 CA COPYRIGHT 1994 ACS
AN CA108(25):219500v CA
TI Coagulation activities of plasma microparticles
SO Thromb. Res., 50(1), 145-56
AU Howard, M. A.; Coghlan, M.; David, R.; Pfueller, S. L.
PY 1988

L11 ANSWER 21 OF 45 CA COPYRIGHT 1994 ACS
AN CA108(9):70164d CA
TI Preparation of recombinant protein complex with human
factor VIII:C clotting activity for
treatment of bleeding disorder
SO Eur. Pat. Appl., 17 pp.
IN Burke, Rae Lyn; Rasmussen, Mirella Ezban
PI EP 232112 A2 870812
AI EP 87-300695 870127
PY 1987

L11 ANSWER 22 OF 45 CA COPYRIGHT 1994 ACS
AN CA107(12):102499q CA
TI In vitro characterization of various factor VIII
concentrates

SO Arzneim.-Forsch., 37(7), 753-6
AU Yoshioka, A.; Shima, M.; Nishino, M.; Yoshikawa, N.; Fukui,
H.
PY 1987

L11 ANSWER 23 OF 45 CA COPYRIGHT 1994 ACS
AN CA107(4):28365z CA
TI Deglycosylated human **factor VIII:C**
SO U.S., 13 pp. Cont.-in-part of U.S. 4,495,175.
IN Chavin, Stephen I.; Fay, Philip J.
PI US 4614795 A 860930
AI US 84-570728 840113
PY 1986

L11 ANSWER 24 OF 45 CA COPYRIGHT 1994 ACS
AN CA106(26):219573e CA
TI Separation of antifactor VIII:C antibodies, especially for
use in
 the blood plasma purification of a type A hemophilic
SO Eur. Pat. Appl., 15 pp.
IN Belattar, Nouredine; Gulino, Danielle; Jozefonvicz,
Jacqueline
PI EP 203865 A1 861203
AI EP 86-401115 860527
PY 1986

L11 ANSWER 25 OF 45 CA COPYRIGHT 1994 ACS
AN CA106(24):201672b CA
TI Interactions between derivatives of insoluble polystyrene
and human
 antibodies to **Factor VIII:C**
SO Polym. Sci. Technol. (Plenum), 34(Polym. Med. 2), 127-37
AU Belattar, N.; Gulino, D.; Jozefonvicz, J.; Sultan, Y.
PY 1986

L11 ANSWER 26 OF 45 CA COPYRIGHT 1994 ACS
AN CA105(16):139598f CA
TI **Preparation** for the treatment of hemophilia A inhibitor
patients
SO PCT Int. Appl., 32 pp.
IN Nordfang, Ole; Rasmussen, Mirella Ezban
PI WO 8602838 A1 860522
AI WO 85-DK105 851105
PY 1986

L11 ANSWER 27 OF 45 CA COPYRIGHT 1994 ACS
AN CA104(11):84826a CA
TI **Factor VIII:C** assay standardization
SO Dev. Hematol. Immunol., 13(Plasma Fractionation Blood
Transfus.),
 217-22
AU Das, P. C.; Thijssen, P. H. M. J.; McShine, R. L.; Sibinga,
C. T.

PY Smit
1985

L11 ANSWER 28 OF 45 CA COPYRIGHT 1994 ACS
AN CA104(5):29838f CA
TI Recombinant **factor VIII-C**
SO Eur. Pat. Appl., 25 pp.
IN Drohan, William Nash; Ricca, George A.; Lee, Sally S. G.
PI EP 157556 A2 851009
AI EP 85-301992 850322
PY 1985

L11 ANSWER 29 OF 45 CA COPYRIGHT 1994 ACS
AN CA103(13):103478m CA
TI Isolation and culture of adrenal medullary endothelial cells
producing blood clotting **Factor VIII:C**
SO U. S. Pat. Appl., 36 pp. Avail. NTIS Order No.
PAT-APPL-6-672 451.
IN Pollard, H. B.
PI US 672451 A0 850510
AI US 84-672451 841116
PY 1985

L11 ANSWER 30 OF 45 CA COPYRIGHT 1994 ACS
AN CA103(12):92685y CA
TI Isolation of human **factor VIII:C** by
preparative high-performance size-exclusion chromatography
SO J. Chromatogr., 326, 217-24
AU Herring, Steven W.; Shitanishi, Kenneth T.; Moody,
Katherine E.;
Enns, Russel K.
PY 1985

L11 ANSWER 31 OF 45 CA COPYRIGHT 1994 ACS
AN CA103(11):82729b CA
TI Production of factor VIII and related products
SO PCT Int. Appl., 72 pp.
IN Toole, John J., Jr.
PI WO 8501961 A1 850509
AI WO 84-US1641 841012
PY 1985

L11 ANSWER 32 OF 45 CA COPYRIGHT 1994 ACS
AN CA103(10):76114f CA
TI In vitro characterization of the human plasma fraction
factor VIII
concentrate
SO Pharmazie, 40(4), 270
AU Uteg, K. H.; Tausendfreund, K.; Schoessler, W.
PY 1985

L11 ANSWER 33 OF 45 CA COPYRIGHT 1994 ACS
AN CA103(10):76110b CA

TI Use of segments for the quality control of factor VIII:
coagulant

activity of fresh frozen plasma

SO Vox Sang., 48(4), 213-16

AU Ofosu, F. A.; Blajchman, M. A.; Kaegi, A.; Turc, J. M.

PY 1985

L11 ANSWER 34 OF 45 CA COPYRIGHT 1994 ACS

AN CA102(19):164974w CA

TI Dependence of the factor VIII activity on blood groups

SO Pharmazie, 40(1), 57-8

AU Uteg, K. H.; Tausendfreund, K.

PY 1985

L11 ANSWER 35 OF 45 CA COPYRIGHT 1994 ACS

AN CA102(10):84390n CA

TI Factor VIII coagulant polypeptides and monoclonal
antibodies to them

SO Eur. Pat. Appl., 46 pp.

IN Zimmerman, Theodore S.; Fulcher, Carol A.

PI EP 123945 A1 841107

AI EP 84-103630 840402

PY 1984

L11 ANSWER 36 OF 45 CA COPYRIGHT 1994 ACS

AN CA101(17):147234s CA

TI Purification of the factor VIII complex

SO Thromb. Res., 35(4), 431-50

AU Thorell, Lars; Blombaeck, Birger

PY 1984

L11 ANSWER 37 OF 45 CA COPYRIGHT 1994 ACS

AN CA101(3):21178h CA

TI Kinetic studies of the activation of factor X by factors
IXa and

VIII:C in the absence of thrombin

SO Br. J. Haematol., 57(1), 123-31

AU Neal, Gregory G.; Esnouf, M. Peter

PY 1984

L11 ANSWER 38 OF 45 CA COPYRIGHT 1994 ACS

AN CA100(9):64380q CA

TI Deterioration of factor VIII:C in
stored plasma for use in activity curves

SO Lab. Med., 15(1), 40-1

AU Palkuti, Harlene S.

PY 1984

L11 ANSWER 39 OF 45 CA COPYRIGHT 1994 ACS

AN CA100(3):20025y CA

TI Standardization of factor VIII - IV. Establishment of the
3rd

International Standard for factor VIII:C

concentrate
SO Thromb. Haemostasis, 50(3), 697-702
AU Barrowcliffe, T. W.; Curtis, A. D.; Thomas, D. P.
PY 1983

L11 ANSWER 40 OF 45 CA COPYRIGHT 1994 ACS
AN CA99(16):128326x CA
TI Blood coagulation **Factor VIII:C**
SO U.S., 6 pp.
IN Johnson, John H.
PI US 4397841 A 830809
AI US 82-392929 820628
PY 1983

L11 ANSWER 41 OF 45 CA COPYRIGHT 1994 ACS
AN CA97(8):60863w CA
TI Control of large-scale plasma thawing for recovery of cryoprecipitate factor VIII
SO Vox Sang., 42(4), 180-9
AU Foster, Peter R.; Dickson, Alan J.; McQuillan, Thomas A.; Dickson, Ida H.; Keddie, Samuel; Watt, John G.
PY 1982

L11 ANSWER 42 OF 45 CA COPYRIGHT 1994 ACS
AN CA96(25):213755u CA
TI Porcine **factor VIII:C prepared**
by affinity interaction with von Willebrand factor and heterologous antibodies: sodium dodecyl sulfate polyacrylamide gel analysis
SO Blood, 59(3), 615-24
AU Knutson, Gaylord J.; Fass, David N.
PY 1982

L11 ANSWER 43 OF 45 CA COPYRIGHT 1994 ACS
AN CA93(10):101409r CA
TI In vitro and in vivo characterization of factor VIII **preparations**
SO Vox Sang., 38(2), 68-80
AU Allain, J. P.; Verroust, F.; Soulier, J. P.
PY 1980

L11 ANSWER 44 OF 45 CA COPYRIGHT 1994 ACS
AN CA90(16):127439p CA
TI The properties of factor VIII coagulant activity **prepared** by immunoadsorbent chromatography
SO J. Lab. Clin. Med., 93(1), 40-53
AU Tuddenham, Edward G. D.; Trabold, Norma C.; Collins, John A.; Hoyer, Leon W.
PY 1979

L11 ANSWER 45 OF 45 CA COPYRIGHT 1994 ACS
AN CA89(7):55806k CA
TI Purification of F.VIII:C by
antigen-antibody chromatography
SO Thromb. Res., 12(4), 667-75
AU Holmberg, L.; Ljung, R.
PY 1978

L12 20 L6 NOT L11

=> d 1-20 an ti so au pi ai py;s freudenberg, w?/au

L12 ANSWER 1 OF 20 CA COPYRIGHT 1994 ACS
AN CA119(22):233771t CA
TI Method for manufacturing chemically virus-inactivated, high
purity
factor VIII concentrate with an overall yield of 35%
feasible for
small pool production in developing countries
SO Colloq. INSERM, 227(Biotechnology of Blood Proteins), 103-8
AU Wallevik, Knut; Glavind, Goeren; Hansen, Eva; Ingerslev,
Joergen;
Joergensen, Jan
PY 1993

L12 ANSWER 2 OF 20 CA COPYRIGHT 1994 ACS
AN CA116(26):262341w CA
TI Chromatographic preparation of a therapeutic highly
purified von
Willebrand factor concentrate from human cryoprecipitate
SO Vox Sang., 62(1), 1-11
AU Burnouf-Radosevich, M.; Burnouf, T.
PY 1992

L12 ANSWER 3 OF 20 CA COPYRIGHT 1994 ACS
AN CA116(4):27900u CA
TI Ultrapure plasma factor VIII produced by anti-F VIIIc
immunoaffinity chromatography and solvent/detergent viral
inactivation. Characterization of the Method M process and
Hemofil M
antihemophilic factor (human)
SO Ann. Hematol., 63(3), 131-7
AU Griffith, M.
PY 1991

L12 ANSWER 4 OF 20 CA COPYRIGHT 1994 ACS
AN CA115(24):263169n CA
TI Removal of parvovirus B19 from contaminated factor VIII
during
fractionation
SO J. Med. Virol., 35(1), 28-31
AU Schwarz, Tino F.; Roggendorf, Michael; Hottentraeger,
Barbara;

Stolz, Wilhelm; Schwinn, Horst
PY 1991

L12 ANSWER 5 OF 20 CA COPYRIGHT 1994 ACS
AN CA114(18):171102m CA
TI High-purity factor VIII concentrates produced without using
monoclonal antibodies
SO Ric. Clin. Lab., 20(4), 227-37
AU Mannucci, Pier Mannuccio; Gringeri, Alessandro; Cattaneo,
Marco
PY 1990

L12 ANSWER 6 OF 20 CA COPYRIGHT 1994 ACS
AN CA114(17):161836q CA
TI von Willebrand factor in lysates of washed canine platelets
SO Am. J. Vet. Res., 52(1), 119-25
AU Parker, Michael T.; Turrentine, Mark A.; Johnson, Gary S.
PY 1991

L12 ANSWER 7 OF 20 CA COPYRIGHT 1994 ACS
AN CA114(15):135521p CA
TI Comparative evaluation of the pharmacokinetics of three
monoclonal
factor VIII concentrates
SO Thromb. Res., 61(3), 285-90
AU Morfini, M.; Mannucci, P. M.; Longo, G.; Cinotti, S.;
Messori, A.
PY 1991

L12 ANSWER 8 OF 20 CA COPYRIGHT 1994 ACS
AN CA114(7):58483y CA
TI Removal of process chemicals from labile biological
mixtures by
hydrophobic interaction chromatography
SO Eur. Pat. Appl., 11 pp.
IN Bonomo, Richard J.
PI EP 366946 A1 900509
AI EP 89-118199 890930
PY 1990

L12 ANSWER 9 OF 20 CA COPYRIGHT 1994 ACS
AN CA113(12):103341t CA
TI Biochemical and physical properties of a solvent-detergent
-treated fibrin glue
SO Vox Sang., 58(2), 77-84
AU Burnouf-Radosevich, Miryana; Burnouf, T.; Huart, J. J.
PY 1990

L12 ANSWER 10 OF 20 CA COPYRIGHT 1994 ACS
AN CA112(3):18399c CA
TI A plasma Factor VIII:C
concentrate purified by immunoaffinity chromatography
SO Colloq. INSERM, 175(Biotechnol. Proteines Plasma), 263-70

AU Liu, S.; Addiego, J.; Comperts, E.; Kessler, C.; Garanchon,
L.;
Neslund, G.; Foster, V.; Berkebile, R.; Courter, S.; et al.
PY 1989

L12 ANSWER 11 OF 20 CA COPYRIGHT 1994 ACS
AN CA106(26):219422e CA
TI Tri(n-butyl) phosphate/~~detergent~~ treatment of licensed
therapeutic and experimental blood derivatives
SO Vox Sang., 52(1-2), 53-9
AU Edwards, Carol A.; Piet, Marcel P. J.; Chin, Sing;
Horowitz, Bernard
PY 1987

L12 ANSWER 12 OF 20 CA COPYRIGHT 1994 ACS
AN CA104(8):56264x CA
TI Inactivation of viruses in labile blood derivatives. I.
Disruption
of lipid-enveloped viruses by tri(n-butyl)phosphate
~~detergent~~ combinations
SO Transfusion (Philadelphia), 25(6), 516-22
AU Horowitz, B.; Wiebe, M. E.; Lippin, A.; Stryker, M. H.
PY 1985

L12 ANSWER 13 OF 20 CA COPYRIGHT 1994 ACS
AN CA103(7):51852g CA
TI Multimeric analysis of von Willebrand factor in
megakaryocytes
SO Thromb. Res., 38(6), 603-10
AU Kupinski, John M.; Miller, Jonathan L.
PY 1985

L12 ANSWER 14 OF 20 CA COPYRIGHT 1994 ACS
AN CA103(5):35829z CA
TI Monoclonal antibodies against the human factor VIII von
Willebrand
molecule: characterization and potential for screening of
von
Willebrand patients
SO Dev. Biol. Stand., 57(Monoclonal Antibodies), 69-76
AU Avner, P.; Arnaud, Danielle; Sultan, Yvette; Maisonneuve,
Pascale;
Jeanneau, Christine
PY 1984

L12 ANSWER 15 OF 20 CA COPYRIGHT 1994 ACS
AN CA102(21):183123j CA
TI Endothelial cell synthesis of von Willebrand antigen II, von
Willebrand factor, and von Willebrand factor/von Willebrand
antigen
II complex
SO J. Clin. Invest., 75(4), 1089-95
AU McCarroll, David R.; Levin, Eugene G.; Montgomery, Robert R.

PY 1985

L12 ANSWER 16 OF 20 CA COPYRIGHT 1994 ACS
AN CA102(16):137785d CA
TI Undenatured virus-free biologically active protein
derivatives
SO Eur. Pat. Appl., 34 pp.
IN Neurath, Alexander Robert; Horowitz, Bernhard
PI EP 131740 A2 850123
AI EP 84-106557 840608
PY 1985

L12 ANSWER 17 OF 20 CA COPYRIGHT 1994 ACS
AN CA102(13):110554r CA
TI Cleavage of human von Willebrand factor by platelet
calcium-activated protease
SO Blood, 65(2), 352-6
AU Kunicki, Thomas J.; Montgomery, Robert R.; Schullek, John
PY 1985

L12 ANSWER 18 OF 20 CA COPYRIGHT 1994 ACS
AN CA102(4):32228w CA
TI Sterilized plasma and plasma derivatives
SO U.S., 8 pp.
IN Prince, Alfred M.
PI US 4481189 A 841106
AI US 82-368250 820414
PY 1984

L12 ANSWER 19 OF 20 CA COPYRIGHT 1994 ACS
AN CA94(7):43681f CA
TI Reconstitution of liposomes bearing platelet receptors for
human von
Willebrand factor
SO Biochem. Biophys. Res. Commun., 97(1), 133-8
AU Sie, P.; Gillois, M.; Boneu, B.; Chap, H.; Bierme, R.;
Dousté-Blazy,
L.
PY 1980

L12 ANSWER 20 OF 20 CA COPYRIGHT 1994 ACS
AN CA77(19):124371f CA
TI Antihemophilic factor. Separation of an active fragment
following
dissociation by salts or detergents
SO Thromb. Diath. Haemorrh., 27(3), 502-15
AU Owen, W. G.; Wagner, Robert H.
PY 1972

L13 15 FREUDENBERG, W?/AU

=> dis his

(FILE 'HOME' ENTERED AT 13:21:56 ON 03 JUN 94)
SET PAGELength SCROLL

FILE 'REGISTRY' ENTERED AT 13:23:09 ON 03 JUN 94

E FACTOR VIII/CN
L1 3 S E3
E F VIII C/CN

FILE 'CA' ENTERED AT 13:24:01 ON 03 JUN 94

L2 3786 S (L1 OR ((FACTOR OR F) (W)VIII(W)C)/IA)
L3 36 S L2 AND (ORGANIC POLYMER OR DETERGENT)/IA
L4 23 S L3 AND PLASMA/IA
L5 3 S L4 AND (STABIL? OR STABL? OR BUFFER?)/IA
L6 20 S L4 NOT L5
L7 0 S L6 AND (AMINO ACID OR (ARGININE AND GLYCINE)
OR (ARG AN
L8 0 S L6 AND CARBOHYDRATE?/IA
L9 200 S (((FACTOR OR F) (W)VIII(W)C)/IA)
L10 46 S L9 AND (PREPAR? OR PREPN)/IA
L11 45 S L10 NOT L5
L12 20 S L6 NOT L11
L13 15 S FREUDENBERG, W?/AU

=> s l13 not (l5 or l6 or l11)

L14 15 L13 NOT (L5 OR L6 OR L11)

=> s l14 and l2

L15 1 L14 AND L2

=> d .mh;s l14 not l15

L15 ANSWER 1 OF 1 CA COPYRIGHT 1994 ACS

TI Stabilization of blood coagulation factor VIII with amino acids

SO Eur. Pat. Appl., 6 pp.

IN Freudenberg, Wilfried

PI EP 508194 A1 921014

AI EP 92-104944 920321

PY 1992

AN CA117(26):258195e CA

AB Stabilizers for blood coagulation factor VIIIC in conc. aq. soln.,

comprise an amino acid and, optionally, an org. polymer or a nonionic surfactant. An aq. soln. of 1% sucrose, 0.M glycine, 0.14M

arginine, 0.1M NaCl, and 0.05% Tween-80, used at a 1:1 vol. ratio,

stabilized a coagulation factor VIIIC eluate (1,860 IU/mg/protein),

purified by immune-affinity chromatog.

L16 14 L14 NOT L15

=> d 1-14 an ti so au ai pi py

L16 ANSWER 1 OF 14 CA COPYRIGHT 1994 ACS
AN CA120(5):50032d CA
TI Thermal inactivation of viruses in protein preparations
SO Eur. Pat. Appl., 8 pp.
IN Keuper, Hermann; Matzmorr, Walter; Freudenberg, Wilfried
AI EP 93-106848 930428
PI EP 571771 A2 931201
PY 1993

L16 ANSWER 2 OF 14 CA COPYRIGHT 1994 ACS
AN CA116(7):54080h CA
TI Electron-transferring flavoproteins from
glycine-metabolizing
anaerobic bacteria
SO Flavins Flavoproteins Proc. Int. Symp., 10th, Meeting Date
1990,
611-14. Edited by: Curti, Bruno; Ronchi, Severino; Zanetti,
Giuliana. de Gruyter: Berlin, Fed. Rep. Ger.
AU Dietrichs, D.; Meyer, M.; Uhde, A.; Freudenberg, W.;
Andreesen, J.
R.
PY 1991

L16 ANSWER 3 OF 14 CA COPYRIGHT 1994 ACS
AN CA114(19):184811s CA
TI Preparation of granular sodium acetate trihydrate
SO Ger. (East), 3 pp.
IN Freudenberg, Werner; Heidrich, Matthias; Hoenisch,
Dietrich; Kniest,
Steffen; Wegner, Joachim; Boeber, Reinhard; Peter,
Siegfried; Wand,
Bernhard
AI DD 89-333833 891024
PI DD 285591 A5 901219
PY 1990

L16 ANSWER 4 OF 14 CA COPYRIGHT 1994 ACS
AN CA112(20):181861f CA
TI Alkali metal carboxylate granules of high bulk density and
constant
particle size
SO Ger. (East), 3 pp.
IN Boeber, Reinhard; Peter, Siegfried; Prahl, Wolfgang;
Litzke, Ursula;
Wand, Bernhard; Kniest, Steffen; Freudenberg, Werner;
Wegner,
Joachim
AI DD 88-317420 880701
PI DD 273627 A1 891122

PY 1989

L16 ANSWER 5 OF 14 CA COPYRIGHT 1994 ACS

AN CA112(19):175285e CA

TI Involvement of a selenoprotein in glycine, sarcosine, and betaine

reduction by Eubacterium acidaminophilum

SO Selenium Biol. Med., [Proc. Int. Symp.], 4th, Meeting Date 1988,

25-8. Edited by: Wendel, Albrecht. Springer: Berlin, Fed. Rep.

Ger.

AU Freudenberg, W.; Hormann, K.; Rieth, M.; Andreesen, J. R.

PY 1989

L16 ANSWER 6 OF 14 CA COPYRIGHT 1994 ACS

AN CA111(11):93621b CA

TI Immunocytochemical localization of proteins P1, P2, P3 of glycine

decarboxylase and of the selenoprotein PA of glycine reductase, all

involved in anaerobic glycine metabolism of Eubacterium acidaminophilum

SO Arch. Microbiol., 152(2), 182-8

AU Freudenberg, W.; Mayer, F.; Andreesen, J. R.

PY 1989

L16 ANSWER 7 OF 14 CA COPYRIGHT 1994 ACS

AN CA110(21):188299w CA

TI Purification and partial characterization of the glycine decarboxylase multienzyme complex from Eubacterium

acidaminophilum

SO J. Bacteriol., 171(4), 2209-15

AU Freudenberg, Wilfried; Andreesen, Jan Remmer

PY 1989

L16 ANSWER 8 OF 14 CA COPYRIGHT 1994 ACS

AN CA110(19):168932u CA

TI Isolation of an atypically small lipoamide dehydrogenase involved in

the glycine decarboxylase complex from Eubacterium acidaminophilum

SO J. Bacteriol., 171(3), 1346-54

AU Freudenberg, Wilfried; Dietrichs, Daniel; Lebertz, Herbert; Andreesen, Jan Remmer

PY 1989

L16 ANSWER 9 OF 14 CA COPYRIGHT 1994 ACS

AN CA109(17):145983b CA

TI Eubacterium acidaminophilum sp. nov., a versatile amino acid-degrading anaerobe producing or utilizing hydrogen or formate.

Description and enzymic studies

SO Arch. Microbiol., 150(3), 254-66
AU Zindel, U.; Freudenberg, W.; Rieth, M.; Andreesen, J. R.;
Schnell,
J.; Widdel, F.
PY 1988

L16 ANSWER 10 OF 14 CA COPYRIGHT 1994 ACS
AN CA109(17):145043v CA
TI Nicotine dehydrogenase from Arthrobacter oxidans: a
molybdenum-containing hydroxylase
SO FEMS Microbiol. Lett., 52(1-2), 13-17
AU Freudenberg, Wilfried; Koenig, Kerstin; Andreesen, Jan
Remmer
PY 1988

L16 ANSWER 11 OF 14 CA COPYRIGHT 1994 ACS
AN CA107(9):76126u CA
TI Improvement of the useful properties of a biolipid extract
SO Ger. (East), 4 pp.
IN Freudenberg, Werner; Poetzsch, Armin; Gedecke, Guenther
AI DD 85-275442 850423
PI DD 236551 A1 860611
PY 1986

L16 ANSWER 12 OF 14 CA COPYRIGHT 1994 ACS
AN CA104(14):111813c CA
TI Synthetic wax
SO Ger. (East), 3 pp.
IN Freudenberg, Werner; Poetzsch, Armin
AI DD 84-264847 840702
PI DD 225422 A1 850731
PY 1985

L16 ANSWER 13 OF 14 CA COPYRIGHT 1994 ACS
AN CA96(16):128963r CA
TI Catalyst and methods for afterburning of waste products from
paraffin oxidation
SO Ger. (East), 8 pp.
IN Freudenberg, Werner; Straube, Joachim
AI DD 80-221107 800515
PI DD 150600 Z 810909
PY 1981

L16 ANSWER 14 OF 14 CA COPYRIGHT 1994 ACS
AN CA95(7):61517g CA
TI Sodium acetate trihydrate
SO Ger. (East), 5 pp.
IN Freudenberg, Werner; Iltzsche, Gerhard; Kroeber, Erhard;
Schmidt,
Rudi
AI DD 78-209138 781117
PI DD 145855 810114
PY 1981

=> fil .biotech
FILE 'BIOSIS' ENTERED AT 13:30:51 ON 03 JUN 94
COPYRIGHT (C) 1994 BIOSIS(R)

FILE 'MEDLINE' ENTERED AT 13:30:51 ON 03 JUN 94

FILE 'EMBASE' ENTERED AT 13:30:51 ON 03 JUN 94
COPYRIGHT (C) 1994 Elsevier Science B.V. All rights reserved.

=> s (factor or f)(W)viii(w)c
FILE 'BIOSIS'
306697 FACTOR
106685 F
11867 VIII
561641 C
L17 441 (FACTOR OR F)(W)VIII(W)C

FILE 'MEDLINE'
238659 FACTOR
62555 F
13095 VIII
368536 C
L18 383 (FACTOR OR F)(W)VIII(W)C

FILE 'EMBASE'
265740 FACTOR
58205 F
9726 VIII
369835 C
L19 181 (FACTOR OR F)(W)VIII(W)C

TOTAL FOR ALL FILES
L20 1005 (FACTOR OR F)(W) VIII(W) C

=> s l20 and freudenberg w?/au
FILE 'BIOSIS'
7 FREUDENBERG W?/AU
L21 0 L17 AND FREUDENBERG W?/AU

FILE 'MEDLINE'
2 FREUDENBERG W?/AU
L22 0 L18 AND FREUDENBERG W?/AU

FILE 'EMBASE'
3 FREUDENBERG W?/AU
L23 0 L19 AND FREUDENBERG W?/AU

TOTAL FOR ALL FILES
L24 0 L20 AND FREUDENBERG W?/AU

=> s l20 and (organic polymer or detergent)
FILE 'BIOSIS'

79828 ORGANIC
14764 POLYMER
54 ORGANIC POLYMER
(ORGANIC(W) POLYMER)
18023 DETERGENT
L25 4 L17 AND (ORGANIC POLYMER OR DETERGENT)

FILE 'MEDLINE'
36083 "ORGANIC"
8110 "POLYMER"
19 ORGANIC POLYMER
("ORGANIC" (W) "POLYMER")
12405 DETERGENT
L26 5 L18 AND (ORGANIC POLYMER OR DETERGENT)

FILE 'EMBASE'
42290 "ORGANIC"
10914 "POLYMER"
36 ORGANIC POLYMER
("ORGANIC" (W) "POLYMER")
11643 DETERGENT
L27 1 L19 AND (ORGANIC POLYMER OR DETERGENT)

TOTAL FOR ALL FILES
L28 10 L20 AND (ORGANIC POLYMER OR DETERGENT)

=> dup rem l28
PROCESSING COMPLETED FOR L28
L29 5 DUP REM L28 (5 DUPLICATES REMOVED)

=> d an ti so au ab 1-5

L29 ANSWER 1 OF 5 BIOSIS COPYRIGHT 1994 BIOSIS DUPLICATE
1

AN 93:114344 BIOSIS
TI VIRUS INACTIVATION OF FRESH FROZEN PLASMA BY A SOLVENT
DETERGENT PROCEDURE BIOLOGICAL RESULTS.
SO VOX SANG 63 (4). 1992. 251-256. CODEN: VOSAAD ISSN:
0042-9007
AU PIQUET Y; JANVIER G; SELOSSE P; DOUTREMEPUICH C; JOUNEAU J;
NICOLLE

G; PLATEL D; VEZON G
AB In order to increase the safety of blood products, we have
developed
a procedure for the virus inactivation of fresh frozen
plasma.
Several batches have been prepared and with the first 10
batches,
each of them composed of 60 litres of plasma, we have
determined a
set of biological parameters. Virus inactivation was
realised using
TnBP (1%) and Octoxynol 9 (1%). After their elimination with
castor

oil using chromatography on insolubilized C18 resin, glycine was added and the pH of the plasma was adjusted to 7.4. Plastic bags were aseptically filled with a mean volume of 200 ml of plasma. The mean levels of coagulation factors were all over 0.7 U/ml and their recovery from initial plasma was nearly the same as total protein except for factor VIII:C. The net loss in factor VIII:C was 16%, when including the dilution of plasma. In vivo and in vitro tests demonstrated that in the final product there were no activated factors. As in fresh frozen plasma, the protein concentrations was over 50 g/l and the potassium level lower than 5 mmol/l. According to these results, virus-inactivated plasma has the same qualities of fresh frozen plasma and could now replace it.

L29 ANSWER 2 OF 5 BIOSIS COPYRIGHT 1994 BIOSIS DUPLICATE
2
AN 92:214745 BIOSIS
TI CLINICAL AND BIOLOGICAL EVALUATION IN VON WILLEBRAND'S
DISEASE OF A
VON WILLEBRAND FACTOR CONCENTRATE WITH LOW FACTOR VIII
ACTIVITY.
SO BR J HAEMATOL 80 (2). 1992. 214-221. CODEN: BJHEAL ISSN:
0007-1048
AU GOUDEMAND J; MAZURIER C; MAREY A; CARON C; COUPEZ B; MIZON P;
GOUDEMAND M
AB This study was carried out to assess the clinical efficacy
in von
Willebrand's disease (vWD) of a new, very high purity (VHP),
solvent/
detergent (SD)-treated, vWF concentrate (VHP Human von
Willebrand Factor Concentrate, Biotransfusion) characterized
by a
high specific ristocetin cofactor (vWF:RCo) activity and a
low factor
VIII (FVIII) coagulant activity (FVIII:C). Nine patients
(four type
I, one type IIA, one type IIB, one type IIC, one type III
and one
acquired type II) were infused on 13 occasions including a
pharmacokinetic study. Satisfactory haemostasis was achieved
in all
cases, including the treatment of spontaneous haemorrhages
and the
prevention of bleeding following surgery. The bleeding time
was

corrected for 6-12 h in 6/9 patients and shortened in the others.

Furthermore, it was shown that the plasma vWF multimeric pattern of

types II and III patients was greatly improved. When measured in

eight patients 1 h after infusion, the vWF:RCo recovery was 77.3

(\pm 10.7)% while the F VIII:C

recovery was strikingly higher (876 \pm 906%). This high recovery is

likely related to the predominant 'pseudo-synthesis' of FVIII following the restoration of normal vWF levels. Maximum levels of

FVIII:C occurred 6-12 h after the first infusion and normal levels of

FVIII:C were maintained throughout the treatments with a dosage of

26-39 IU/kg vWF:RCo and only 0.2-5 IU/kg FVIII:C. The half-lives of

the vWF-related parameters determined in a type III vWD patient were

20.6 h for vWF antigen, 17.8 h for vWF:RCo, 14 h for the high molecular weight multimers of vWF, 55.3 h for FVIII:Ag and 74 h for

FVIII:C. In conclusion, it does not appear necessary that vWF concentrations intended for the treatment of vWD should contain FVIII

in addition to vWF to be clinically effective in most patients.

L29 ANSWER 3 OF 5 MEDLINE 1994

AN 92031935 MEDLINE

TI Ultrapure plasma factor VIII produced by anti-F VIII c immunoaffinity chromatography and solvent/detergent viral inactivation. Characterization of the Method M process and Hemofil M antihemophilic factor (human).

SO Ann Hematol, (1991 Sep) 63 (3) 131-7. Ref: 13

Journal code: A2P. ISSN: 0939-5555.

AU Griffith M

L29 ANSWER 4 OF 5 BIOSIS COPYRIGHT 1994 BIOSIS DUPLICATE
3

AN 90:86697 BIOSIS

TI PROGRESS IN PURIFICATION OF VIRUS-INACTIVATED FACTOR VIII CONCENTRATES THREE GENERATIONS OF SOLVENT-DETERGENT TREATED PLASMA DERIVATIVES.

SO ARZNEIM-FORSCH 39 (10). 1989. 1302-1305. CODEN: ARZNAD ISSN: 0004-4172

AU SCHWINN H; SMITH A; WOLTER D

AB A production process of a newly developed highly purified and virus-inactivated Factor (F) VIII-concentrate (Octa V.I. and Octavi)

is presented. Taking advantage of a selective resin matrix and the solvent/~~detergent~~ procedure for virus inactivation - known not to denature proteins - a product of a specific activity .gtoreq. 100 IU F VIII/mg could be developed in the final container without the use of an immuno-affinity adsorption step. The main steps of the procedure are; Pooled cryoprecipitate is extracted, the extract is cleared from fibrinogen at + 10.degree. C and virus-inactivated at + 28.degree. C after addition of tributyl-phosphate (TNBP) and ~~detergent~~. Thereafter the extract is brought in contact to a F VIII-selective anion exchange resin using a chromatographic column. TnBP and the ~~detergent~~ are removed by an extensive washing process and the F VIII-activity is concentrated in a fraction, ready for filling, by means of a cascade of washing- and elution-buffers. The product is free from coagulable protein and gamma-globulins. The F VIIIC: Ag/F VIII:C-ratio is about unity, suggesting the F VIII-molecule remained in its native state. The development of highly purified F VIII concentrate is based on two previous products of lesser purity (spec. activity of about 1 and 10 IU/mg). The evolution is shown by a comparison of detailed analytical data.

L29 ANSWER 5 OF 5 BIOSIS COPYRIGHT 1994 BIOSIS DUPLICATE
4

AN 90:816 BIOSIS

TI COMPARISON OF THE IN-VITRO CHARACTERISTICS OF VON WILLEBRAND
FACTOR

IN BRITISH AND COMMERCIAL FACTOR VIII CONCENTRATES.

SO BR J HAEMATOL 73 (1). 1989. 100-104. CODEN: BJHEAL ISSN:
0007-1048

AU LAWRIE A S; HARRISON P; ARMSTRONG A L; WILBOURN B R; DALTON
R G;

SAVIDGE G F

AB Qualitative/quantitative analysis of von Willebrand factor
antigen

(vWf:Ag) in either heat or solvent/~~detergent~~ treated factor
VIII concentrates, used for haemophilia replacement therapy,
was

undertaken to assess their suitability for the treatment of
vWD. For

the first time immunoaffinity purified vWf:Ag (Monoclone
by-product)

was also evaluated by in vitro assessment. Potencies of
vWF:Ag varied

considerably but were consistently higher (28.9-420.5 iu/ml) than

factor VIII:C (one-stage) activity (8.13-42.44 iu/ml). The functional activity of vWf was assessed by

either Ristocetin Cofactor (vWf:Rco) or collagen binding methods

(vWf:CBA) with typical vWf:RCo/vWf:Ag ratios from 0.08 to 0.94.

Multimeric analysis confirmed that in vitro biological activity was

dependent on the presence of the high molecular weight forms of

vWf:Ag. A significant correlation ($r = 0.95$) between vWf:RCo activity

and collagen binding was observed in all of the concentrates with the

exception of the immunopurified product. The data suggest that

either NHS 8Y (mean vWfRCo/vWf:Ag = 0.94), Haemate P (mean vWf:RCo/vWf:Ag = 0.69) and high purity Octapharma V.I (vWf:RCo/vWf:Ag

= 0.82) which contain medium/high MW vWf:Ag multimers are likely to

be most cost-effective in the treatment of symptomatic severe vWD

patients than other currently available concentrates.

=> s 120 and (amino acid or (arginine and glycine) or (arg and gly))

FILE 'BIOSIS'

271052 AMINO

669958 ACID

147922 AMINO ACID

(AMINO(W)ACID)

32637 ARGININE

38791 GLYCINE

10715 ARG

11142 GLY

L30 6 L17 AND (AMINO ACID OR (ARGININE AND GLYCINE) OR (ARG AND

GLY))

FILE 'MEDLINE'

249957 "AMINO"

635373 "ACID"

163334 AMINO ACID

("AMINO"(W)"ACID")

27763 ARGININE

21738 GLYCINE

10040 ARG

10315 GLY

L31 11 L18 AND (AMINO ACID OR (ARGININE AND GLYCINE) OR (ARG AND

GLY))

FILE 'EMBASE'

144219 "AMINO"

690306 "ACID"

89376 AMINO ACID

("AMINO"(W)"ACID")

22940 ARGININE

17807 GLYCINE

7827 ARG

8178 GLY

L32 2 L19 AND (AMINO ACID OR (ARGININE AND GLYCINE) OR
(ARG AND

GLY))

TOTAL FOR ALL FILES

L33 19 L20 AND (AMINO ACID OR (ARGININE AND GLYCINE) OR
(ARG AND

GLY))

=> s l33 and carbohydrate

FILE 'BIOSIS'

51920 CARBOHYDRATE

L34 0 L30 AND CARBOHYDRATE

FILE 'MEDLINE'

39683 CARBOHYDRATE

L35 0 L31 AND CARBOHYDRATE

FILE 'EMBASE'

31338 CARBOHYDRATE

L36 0 L32 AND CARBOHYDRATE

TOTAL FOR ALL FILES

L37 0 L33 AND CARBOHYDRATE

=> dup rem l33

PROCESSING COMPLETED FOR L33

L38 12 DUP REM L33 (7 DUPLICATES REMOVED)

=> d an ti so au 1-12

L38 ANSWER 1 OF 12 MEDLINE 1994

AN 91069319 MEDLINE

TI [Chemistry and clinical significance of human plasma
proteins].

Chemie und klinische Bedeutung der Human-Plasmaproteine.

SO Behring Inst Mitt, (1990 Oct) (86) 1-66. Ref: 336

Journal code: 9KI. ISSN: 0301-0457.

AU Haupt H

L38 ANSWER 2 OF 12 BIOSIS COPYRIGHT 1994 BIOSIS DUPLICATE
1

AN 89:178216 BIOSIS
TI IDENTIFICATION OF A FACTOR VIII EPI TOPE RECOGNIZED BY A HUMAN
HEMOPHILIC INHIBITOR.
SO BLOOD 73 (2). 1989. 497-499. CODEN: BLOOAW ISSN: 0006-4971
AU LUBAHN B C; WARE J; STAFFORD D W; REISNER H M

L38 ANSWER 3 OF 12 BIOSIS COPYRIGHT 1994 BIOSIS DUPLICATE
2

AN 89:220165 BIOSIS
TI A MONOCLONAL IMMUNOGLOBULIN A KAPPA FACTOR VII C INHIBITOR
ASSOCIATED
WITH PRIMARY AMYLOIDOSIS IDENTIFICATION AND CHARACTERIZATION.
SO J LAB CLIN MED 113 (3). 1989. 269-277. CODEN: JLCMAK ISSN:
0022-2143
AU GLUECK H I; COOTS M C; BENSON M; DWULET F E; HURTUBISE P E

L38 ANSWER 4 OF 12 MEDLINE 1994

AN 88309004 MEDLINE
TI Synthesis of biologically active deletion mutants of human
factor VIII:C.
SO Behring Inst Mitt, (1988 Apr) (82) 16-25.
Journal code: 9KI. ISSN: 0301-0457.
AU Langner KD; Bird RE; McCandliss R; Huber B; Amann E;
Zettlmeissl G;
Kupper HA

L38 ANSWER 5 OF 12 MEDLINE 1994

AN 86304432 MEDLINE
TI The functional domains of coagulation factor VIII
:C.
SO J Biol Chem, (1986 Sep 25) 261 (27) 12574-8.
Journal code: HIV. ISSN: 0021-9258.
AU Burke RL; Pacht C; Quiroga M; Rosenberg S; Haigwood N;
Nordfang O;
Ezban M

L38 ANSWER 6 OF 12 MEDLINE 1994

AN 86225810 MEDLINE
TI Disseminated intravascular coagulation following Echis
carinatus
venom in dogs: effects of a synthetic thrombin inhibitor.
SO J Lab Clin Med, (1986 Jun) 107 (6) 488-97.
Journal code: IVR. ISSN: 0022-2143.
AU Schaeffer RC Jr; Briston C; Chilton SM; Carlson RW

L38 ANSWER 7 OF 12 MEDLINE 1994

AN 87176513 MEDLINE
TI Desmopressin (DDAVP) for treatment of disorders of
hemostasis.
SO Prog Hemost Thromb, (1986) 8 19-45. Ref: 103
Journal code: Q1B. ISSN: 0362-6350.
AU Mannucci PM

L38 ANSWER 8 OF 12 BIOSIS COPYRIGHT 1994 BIOSIS DUPLICATE
3

AN 86:142385 BIOSIS

TI CHARACTERIZATION OF THE POLYPEPTIDE COMPOSITION OF HUMAN
FACTOR-VIII C AND THE NUCLEOTIDE SEQUENCE
AND EXPRESSION OF THE HUMAN KIDNEY COMPLEMENTARY DNA.

SO DNA (N Y) 4 (5). 1985. 333-350. CODEN: DNAADR ISSN:
0198-0238

AU TRUETT M A; BLACHER R; BURKE R L; CAPUT D; CHU C; DINA D;
HARTOG K;

KUO C H; MASIARZ F R; ET AL

L38 ANSWER 9 OF 12 BIOSIS COPYRIGHT 1994 BIOSIS DUPLICATE
4

AN 84:320514 BIOSIS

TI STABILIZATION OF THROMBIN ACTIVATED PORCINE FACTOR-
VIII C BY FACTOR-IXA AND PHOSPHO LIPID.

SO BLOOD 63 (6). 1984. 1303-1308. CODEN: BLOOAW ISSN: 0006-4971

AU LOLLAR P; KNUTSON G J; FASS D N

L38 ANSWER 10 OF 12 BIOSIS COPYRIGHT 1994 BIOSIS DUPLICATE
5

AN 85:230093 BIOSIS

TI STRUCTURE-FUNCTION RELATIONSHIPS OF HUMAN FACTOR-VIII
COMPLEX STUDIED

BY THIOREDOXIN DEPENDENT DISULFIDE REDUCTION.

SO THROMB RES 35 (6). 1984. 637-652. CODEN: THBRAA ISSN:
0049-3848

AU HESSEL B; JORNVALL H; THORELL L; SODERMAN S; LARSSON U;
EGBERG N;

BLOMBACK B; HOLMGREN A

L38 ANSWER 11 OF 12 MEDLINE 1994

AN 85021377 MEDLINE

TI Inhibition of activated porcine factor IX by
dansyl-glutamyl-glycyl-
arginy-chloromethylketone.

SO Arch Biochem Biophys, (1984 Sep) 233 (2) 438-46.
Journal code: 6SK. ISSN: 0003-9861.

AU Lollar P; Fass DN

L38 ANSWER 12 OF 12 BIOSIS COPYRIGHT 1994 BIOSIS

AN 84:76926 BIOSIS

TI THE MOLECULAR STRUCTURE OF HUMAN FACTOR-VIII
C.

SO 9TH INTERNATIONAL CONGRESS ON THROMBOSIS AND HEMOSTASIS,
JULY 4-8,
1983. THROMB HEMOSTASIS 50 (1). 1983. 262. CODEN: THHADQ
ISSN:

0340-6245

AU KUO G; CRAINE B; MASIARZ F; RALL L; TRUETT M; VALENZUELA P;
NORDFANG

O; EZBAN M

=> dis his l20-

(FILE 'BIOSIS, MEDLINE, EMBASE' ENTERED AT 13:30:51 ON 03 JUN 94)

TOTAL FOR ALL FILES
L20 1005 S (FACTOR OR F) (W) VIII (W) C
FILE 'BIOSIS'
L21 0 S L20 AND FREUDENBERG W?/AU
FILE 'MEDLINE'
L22 0 S L20 AND FREUDENBERG W?/AU
FILE 'EMBASE'
L23 0 S L20 AND FREUDENBERG W?/AU
TOTAL FOR ALL FILES
L24 0 S L20 AND FREUDENBERG W?/AU
FILE 'BIOSIS'
L25 4 S L20 AND (ORGANIC POLYMER OR DETERGENT)
FILE 'MEDLINE'
L26 5 S L20 AND (ORGANIC POLYMER OR DETERGENT)
FILE 'EMBASE'
L27 1 S L20 AND (ORGANIC POLYMER OR DETERGENT)
TOTAL FOR ALL FILES
L28 10 S L20 AND (ORGANIC POLYMER OR DETERGENT)
L29 5 DUP REM L28 (5 DUPLICATES REMOVED)
FILE 'BIOSIS'
L30 6 S L20 AND (AMINO ACID OR (ARGININE AND GLYCINE)
OR (ARG A
FILE 'MEDLINE'
L31 11 S L20 AND (AMINO ACID OR (ARGININE AND GLYCINE)
OR (ARG A
FILE 'EMBASE'
L32 2 S L20 AND (AMINO ACID OR (ARGININE AND GLYCINE)
OR (ARG A
TOTAL FOR ALL FILES
L33 19 S L20 AND (AMINO ACID OR (ARGININE AND GLYCINE)
OR (ARG A
FILE 'BIOSIS'
L34 0 S L33 AND CARBOHYDRATE
FILE 'MEDLINE'
L35 0 S L33 AND CARBOHYDRATE
FILE 'EMBASE'
L36 0 S L33 AND CARBOHYDRATE
TOTAL FOR ALL FILES
L37 0 S L33 AND CARBOHYDRATE
L38 12 DUP REM L33 (7 DUPLICATES REMOVED)

=> s l20 and prepar?

FILE 'BIOSIS'

259218 PREPAR?

L39 49 L17 AND PREPAR?

FILE 'MEDLINE'

228848 PREPAR?

L40 48 L18 AND PREPAR?

FILE 'EMBASE'

204984 PREPAR?

L41 28 L19 AND PREPAR?

TOTAL FOR ALL FILES

L42 125 L20 AND PREPAR?

=> s l42 and (stabil? or stabl?)

FILE 'BIOSIS'

98853 STABIL?

95904 STABL?

L43 9 L39 AND (STABIL? OR STABL?)

FILE 'MEDLINE'

83470 STABIL?

75925 STABL?

L44 8 L40 AND (STABIL? OR STABL?)

FILE 'EMBASE'

74073 STABIL?

70605 STABL?

L45 5 L41 AND (STABIL? OR STABL?)

TOTAL FOR ALL FILES

L46 22 L42 AND (STABIL? OR STABL?)

=> s l46 and coagul?

FILE 'BIOSIS'

39077 COAGUL?

L47 1 L43 AND COAGUL?

FILE 'MEDLINE'

59432 COAGUL?

L48 1 L44 AND COAGUL?

FILE 'EMBASE'

27947 COAGUL?

L49 0 L45 AND COAGUL?

TOTAL FOR ALL FILES

L50 2 L46 AND COAGUL?

=> dup rem l50

PROCESSING COMPLETED FOR L50

L51 1 DUP REM L50 (1 DUPLICATE REMOVED)

=> d an ti so au ab

L51 ANSWER 1 OF 1 BIOSIS COPYRIGHT 1994 BIOSIS

DUPLICATE

1

AN 86:139204 BIOSIS

TI DEGRADATION OF FACTOR-VIII COAGULANT ANTIGEN BY PROTEOLYTIC ENZYMES.

SO BR J HAEMATOL 61 (3). 1985. 477-486. CODEN: BJHEAL ISSN: 0007-1048

AU RICK M E; POPOVSKY M A; KRIZEK D M

AB The factors responsible for the lability for factor VIII coagulant activity (VIII:C) and factor VIII coagulant antigen (VIII:CAg) are poorly understood. In this study the VIII:C

and VIII:CAg are studied after incubation with plasmin, trypsin or

.alpha.-chymotrypsin. Both isolated human VIII:CAg and VIII:CAg

associated with factor VIII-related antigen (VIII R:Ag) are evaluated. The antigenic sites of the VIII:CAg are somewhat more

stable to the action of these enzymes than the functional activity, although both follow a generally parallel degradation. A

biphasic decay curve is seen in the initial time points. No stabilization of the functional or antigenic reactivity is observed in the presence of the VIII R:Ag. Lower

concentrations of

each enzyme cause an initial rise in the factor VIII:C in the presence of VIII R:Ag, but not in the isolated VIII:CAg. Higher concentrations of

.alpha.-chymotrypsin

cause activation of VIII:C and a slight decrease in the VIII:CAg

values in both preparations. These enzymes may play a modulating role in the coagulation cascade through the activation and degradation of VIII:C and VIII:CAg.